Australia markets closed
  • ALL ORDS

    7,503.50
    -50.50 (-0.67%)
     
  • ASX 200

    7,301.50
    -52.90 (-0.72%)
     
  • AUD/USD

    0.6811
    -0.0005 (-0.08%)
     
  • OIL

    80.12
    -1.10 (-1.35%)
     
  • GOLD

    1,811.10
    -4.10 (-0.23%)
     
  • BTC-AUD

    24,948.55
    -101.38 (-0.40%)
     
  • CMC Crypto 200

    403.61
    +2.18 (+0.54%)
     
  • AUD/EUR

    0.6462
    -0.0007 (-0.11%)
     
  • AUD/NZD

    1.0626
    -0.0062 (-0.58%)
     
  • NZX 50

    11,641.85
    -12.71 (-0.11%)
     
  • NASDAQ

    11,992.88
    -49.01 (-0.41%)
     
  • FTSE

    7,556.23
    -2.26 (-0.03%)
     
  • Dow Jones

    34,444.46
    +49.45 (+0.14%)
     
  • DAX

    14,529.39
    +39.09 (+0.27%)
     
  • Hang Seng

    18,675.35
    -61.09 (-0.33%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     

Here's Why This Dividend King Is a Buy

Here's Why This Dividend King Is a Buy

Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.